Activest Wealth Management Decreases Position in IQVIA Holdings Inc. (NYSE:IQV)

Activest Wealth Management trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 66.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 135 shares of the medical research company’s stock after selling 265 shares during the quarter. Activest Wealth Management’s holdings in IQVIA were worth $27,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP purchased a new stake in shares of IQVIA during the third quarter worth about $27,000. Avior Wealth Management LLC boosted its stake in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares in the last quarter. Synergy Asset Management LLC purchased a new stake in IQVIA during the 4th quarter worth approximately $33,000. Assetmark Inc. raised its holdings in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after buying an additional 196 shares during the last quarter. Finally, UMB Bank n.a. lifted its stake in shares of IQVIA by 74.4% during the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after buying an additional 99 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Trading Down 0.9 %

Shares of NYSE:IQV opened at $208.13 on Monday. The firm has a market capitalization of $37.78 billion, a price-to-earnings ratio of 27.75, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48. The business’s 50 day moving average price is $200.67 and its 200-day moving average price is $219.40. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on IQV. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. TD Cowen dropped their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Redburn Atlantic initiated coverage on shares of IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 price target for the company. Finally, Bank of America dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average target price of $252.39.

Insider Buying and Selling at IQVIA

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The shares were purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the purchase, the director now owns 1,275 shares in the company, valued at approximately $255,739.50. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.